Test Price
4,000 AED✅ Home Collection Available
Lung Cancer Panel 6 (EGFR Sequencing, ALK IHC, ROS1 FISH) in UAE
Executive Summary & Core Metrics
✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited processing. All mutations validated with orthogonal methods.
✔ Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks or slides. No home phlebotomy required. Temperature‑controlled transport ensures sample integrity.
✔ Clinical Guidance: Telephonic Post‑Test Clinical Guidance with our DHA‑licensed specialist to interpret results and coordinate next steps.
✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – all major UAE insurers accepted.
Test Overview & Methodology
The Lung Cancer Panel 6 is a comprehensive molecular assay that simultaneously assesses EGFR mutations by Sanger Sequencing, ALK rearrangements by IHC, and ROS1 fusions by FISH from FFPE tumor tissue. This single‑visit, 5‑7 day panel provides oncologists with the actionable biomarkers required to select first‑line targeted therapy, avoiding chemotherapy in eligible patients.
| Parameter | Our Test – Lung Cancer Panel 6 | Closest Alternative (NGS Multigene Panel) |
|---|---|---|
| Precision | >99% sensitivity for EGFR, ALK, ROS1; each method validated individually | Broad NGS often misses ALK fusions; may require orthogonal IHC confirmation |
| Method | Sanger Sequencing (EGFR) + IHC (ALK) + FISH (ROS1) – gold‑standard for fusion detection | DNA‑based NGS alone, limited RNA fusion detection unless ordered as separate RNA NGS |
| Turnaround Time | 5‑7 working days | Typically 10‑14 working days (with reflex testing) |
| Cost‑Effectiveness | 4,000 AED fixed price, insurance‑covered; no hidden charges | Often >5,500 AED with additional IHC/FISH add‑ons |
Physician Insight & Safety Protocols
“This panel provides a critical roadmap for targeted therapy in lung cancer. However, accurate interpretation requires full integration with the patient’s clinical history and imaging. Always discuss results with your treating physician before making any treatment changes.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
⚠ Important Advisory
Do not discontinue prescribed medication without consulting your doctor. Biomarker results must be interpreted within the complete clinical context.
Exclusion Criteria & Emergency Red Flags
- Not for patients without a confirmed histological diagnosis of primary non‑small cell lung carcinoma (NSCLC).
- Insufficient tumor cellularity (<20% tumor nuclei) may yield false‑negative; repeat biopsy required.
- Liquid biopsy (ctDNA) is not a substitute for tissue testing in this panel—only FFPE tumor tissue accepted.
- Testing during active chemotherapy may alter protein expression (ALK IHC); ideally test on pre‑treatment archival tissue.
🚨 Seek immediate emergency care if you experience severe dyspnea, massive hemoptysis, acute chest pain, or signs of superior vena cava syndrome while awaiting results.
Patient FAQ & Clinical Guidance
1. Why do I need the Lung Cancer Panel 6?
The panel detects EGFR, ALK, and ROS1 mutations that directly determine eligibility for targeted oral therapies, often minimizing chemotherapy. Without these results, your oncologist cannot prescribe the most effective, least toxic precision medicine for your specific lung cancer subtype.
2. How do I prepare for the tissue collection?
You need no fasting; the sample is a tumor tissue biopsy typically obtained during a previous bronchoscopy or CT‑guided biopsy procedure. Our service arranges secure medical courier pickup of your already‑collected FFPE block or slides from the hospital’s pathology lab.
3. How long will results take and how are they explained?
Results are reported in 5‑7 working days with a full molecular interpretation and therapy guidance signed by a consultant pathologist. Our DHA‑licensed specialist will call you to explain the report, answer questions, and coordinate the next oncology consultation.
UAE Regulatory & Data Privacy Adherence
All laboratory operations at DNA Labs UAE comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139)
Laboratory Facility License: DHA 1143 | Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | Lung Cancer Panel 6 (EGFR Sequencing, ALK IHC, ROS1 FISH) |
| Price (AED) | 4,000 AED |
| Turnaround Time | 5 – 7 working days |
| Sample Type / Matrix | FFPE Tumor Tissue (Archival specimen) |
| Methodology Used | Sanger Sequencing (EGFR), Immunohistochemistry (ALK), Fluorescence In Situ Hybridization (ROS1) |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of bronchus or lung, unspecified) |
| LOINC Code | 94498-6 (Lung cancer panel) |
| DHA Facility License & Laboratory Address | License No: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians